Marrow Cutter seems fun, I'm not entirely sure that the current roster of low cost heroes is enough to support it, but by no means is it a weak card.
This was initially an Expedition list which is why 80% of it is Expedition cards, I was not happy with its power level there, and after migrating it to throne, for some reason (
Plunk Wumpkin) it performs better, magically, for no reason.
The gameplan is to stick a threat early, preferably one with
aegis, buff it up with weapons, and keep its path clear of blockers.
After getting some early damage in you're usually in a great spot since they are, 1 dead, or 2 depleted since they (hopefully) spent considerable effort and resources removing your threat.
If they are aggro, instead use your versatile weapons as removal and hold out until
Save the Day,which usually gives you enough time to resolve a favorable board state.
I really like
Winter Tomb here, its more expensive than
Permafrost, but it ends up being removal + 5 damage over he course of a game, and gives you some inevitability.
Interestingly enough
Winter Tomb does not fall off after the cursed unit gains endurance which can be relevant.
Keep in mind that while you can have fairly aggressive starts, this is not an aggro list its midrange (I think) and you have a decent fighting chance against control.
Power base wise, Its just Cylix greed, not sure its correct since it would be nice to have consistent undepleted power early, but it pays off in the late game and it hasn't given me too much trouble. That being said its completely understandable to cut back in favor of more marks or
Greater Plans which is also a great fit for the deck.
I almost included 1-2 copies of
Untapped Rift, since it didn't seem too unreasonable to draw 3 late in when there's not much else to do but it messes with the Cylix plan and I decided they were not needed.
Technically correct to run
Purpose Chant instead of
Seek Power, but you don't need them.
Like always I don't think the deck needs a market, but I could be wrong, any feed back is welcome.